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Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor
acute lymphoblastic leukemia and its therapeutic potential
LM Neri1,8, A Cani1,8, AM Martelli2,3, C Simioni1, C Junghanss4, G Tabellini5, F Ricci6, PL Tazzari6, P Pagliaro6, JA McCubrey7
and S Capitani1
B-precursor acute lymphoblastic leukemia (B-pre ALL) is a malignant disorder characterized by the abnormal proliferation of B-cell
progenitors. The prognosis of B-pre ALL has improved in pediatric patients, but the outcome is much less successful in adults.
Constitutive activation of the phosphatidylinositol 3-kinase (PI3K), Akt and the mammalian target of rapamycin (mTOR) (PI3K/Akt/
mTOR) network is a feature of B-pre ALL, where it strongly inﬂuences cell growth and survival. RAD001, a selective mTORC1
inhibitor, has been shown to be cytotoxic against many types of cancer including hematological malignancies. To investigate
whether mTORC1 could represent a target in the therapy of B-pre ALL, we treated cell lines and adult patient primary cells with
RAD001. We documented that RAD001 decreased cell viability, induced cell cycle arrest in G0/G1 phase and caused apoptosis in
B-pre ALL cell lines. Autophagy was also induced, which was important for the RAD001 cytotoxic effect, as downregulation of
Beclin-1 reduced drug cytotoxicity. RAD001 strongly synergized with the novel allosteric Akt inhibitor MK-2206 in both cell lines and
patient samples. Similar results were obtained with the combination CCI-779 plus GSK 690693. These ﬁndings point out that
mTORC1 inhibitors, either as a single agent or in combination with Akt inhibitors, could represent a potential therapeutic innovative
strategy in B-pre ALL.
Leukemia (2014) 28, 739–748; doi:10.1038/leu.2013.226
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INTRODUCTION
B-precursor acute lymphoblastic leukemia (B-pre ALL) is character-
ized by malignant proliferation and accumulation of early lymphoid
precursor cells in the bone marrow, blood and lymphoid organs,1
due to acquired mutations in early B-cells.2,3 B-pre ALL is
predominantly a childhood disease but can occur at any age.
Although the prognosis of B-pre ALL has improved, the outcome of
relapsed and chemoresistant B-pre ALL is still poor, especially in
adults, with a 35–40% survival at 5 years, whereas in children, it is
about 80%.1 Therefore, major efforts are being made to develop
rationally targeted therapies against altered signaling cascades that
sustain leukemia cell proliferation, survival and drug resistance.
The phosphatidylinositol 3-kinase (PI3K), Akt and the
mammalian target of rapamycin (mTOR) (PI3K/Akt/mTOR)
signaling pathway is frequently observed to be deregulated, thus
leading to the pathogenesis of a variety of leukemias4,5 including
acute myeloid leukemia (AML),6 T-cell ALL (T-ALL)7 and B-pre ALL.8
mTOR is a serine/threonine kinase, downstream of Akt, that
controls cell proliferation and survival. mTOR is the catalytic
subunit of two distinct multi-protein complexes, referred to as
mTORC1 and mTORC2.6 mTORC1 phosphorylates the S6 ribosomal
protein kinase (p70S6K) and the initiation factor 4E-binding
protein 1 (4EBP1), which are important in translational
control,9,10 whereas mTORC2 phosphorylates Akt on Ser 473
residue.11 Constitutive activation of PI3K/Akt/mTOR signaling
negatively inﬂuences the response to therapeutic treatments
and correlates with enhanced drug resistance and poor prognosis
in various types of cancer.12,13 Rapamycin, the ﬁrst disclosed
mTORC1 inhibitor, has been shown to exert signiﬁcant in vitro
anti-leukemic activity in ALL14,15 and in B-pre ALL.16 RAD001
(Everolimus; 40-O-(2-hydroxyethyl)-rapamycin) is an orally
bioavailable ester derivative of rapamycin. RAD001 binds the
intracellular protein FK-506-binding protein-12, forming a complex
that inhibits the activity of mTORC1, thus affecting cell cycle
progression, survival, angiogenesis and glycolysis.17 RAD001 has
been shown to be active against many subsets of leukemia, such
as AML and acute promyelocytic leukemia,18 non-Hodgkin’s
lymphoma19 and other hematological malignancies, being under
evaluation in several phase I/II clinical trials.20 However, B-pre ALL
was not included in these trials.
Here, the potential therapeutic efﬁcacy of RAD001 was
examined in B-pre ALL cell lines and adult patient primary cells.
In particular, the drug induced G0/G1 phase cell cycle arrest,
modulated the PI3K/Akt/mTOR pathway and caused apoptosis
and autophagy in a dose-dependent manner. Moreover, dual
treatment combining RAD001 with an allosteric Akt inhibitor, MK-
2206, displayed a dramatic synergistic effect against leukemic
cells. Similar results were obtained with the combination
consisting of CCI-779 (Temsirolimus, another mTORC1 inhibitor21)
and GSK 690693, an ATP-competitive Akt inhibitor.22
These ﬁndings indicate that mTOR inhibition, alone or in
combination with additional drugs targeted to other components
1Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy; 2Department of Biomedical and Neuromotor Sciences, University of Bologna,
Bologna, Italy; 3Institute of Molecular Genetics, National Research Council, Pavia, Italy; 4University of Rostock, Division of Medicine, Department of Hematology/Oncology/
Palliative Medicine, Rostock, Germany; 5Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; 6Immunohematology and Transfusion Center,
Policlinico S.Orsola-Malpighi, Bologna, Italy and 7Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
Correspondence: Dr LM Neri, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
E-mail: luca.neri@unife.it
8These authors contributed equally to this work.
Received 2 May 2013; revised 11 July 2013; accepted 19 July 2013; accepted article preview online 29 July 2013; advance online publication, 23 August 2013
Leukemia (2014) 28, 739–748
& 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14
www.nature.com/leu
of the PI3K/Akt/mTOR signal transduction pathway, could be an
attractive strategy to develop innovative therapeutic protocols for
the treatment of B-pre ALL leukemia patients.
MATERIALS AND METHODS
Materials
Cell Viability Kit or MTT was from Roche Applied Science (Mannheim,
Germany). Annexin V/7-AAD was from Merck-Millipore (Darmstadt,
Germany). For western blotting, primary and secondary antibodies were
provided by Cell Signaling Technology (Danvers, MA, USA). Signals were
detected with the ECL Plus reagent by Perkin Elmer (Boston, MA, USA).
RAD001, CCI-779, MK-2206 and GSK 690693 were purchased from Selleck
Chemicals (Houston, TX, USA). SignalSilence control small interfering RNA
(siRNA) and Beclin-1 siRNA II were obtained from Cell Signaling
Technology.
Cell culture
The B-pre ALL cell lines SEM, REH, RS4;11 and NALM6 were obtained from
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
(Braunschweig, Germany). SEM, REH and NALM6 were grown in RPMI
1640 medium, whereas RS4;11 cells were grown in Alpha-MEM medium,
both supplemented with 10% heat-inactivated fetal bovine serum,
100 units/ml penicillin and 100mg/ml streptomycin.23 The cells were
grown at a density of 0.5 to 0.8 106 cells/ml. Primary samples from adult
B-pre ALL patients (CD10þ / , CD19þ , HLA DRþ and cytoplasmic IgMþ )
were obtained with informed consent according to institutional guidelines.
B-pre ALL patient lymphoblasts were cultured in triplicate in ﬂat-bottomed
96-well plates at 37 1C with 5% CO2 at a density of 2 106 cells/ml, using
RPMI medium supplemented with 20% fetal bovine serum and 2mM
l-glutamine.
Cell viability analysis by MTT assay
MTT (3-(4,5-dimethylthythiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays
were performed as previously described.24
Western blot analysis
For protein extraction, 2 106 cells were washed in PBS and lysed with
RIPA buffer (50mM Tris HCl pH 7.4, 150mM NaCl, 0.1% SDS and 1% NP40),
including protease and phosphatase inhibitors obtained from Roche
Applied Science. Samples were incubated for 30min at 4 1C, and cell
extracts were sonicated and centrifuged at 13 000 g for 10min at 4 1C.
Protein concentration was assayed using the BCA Protein Assay (Euroclone,
Milan, Italy). Samples were loaded on a polyacrylamide gel for electro-
phoresis separation and transferred to a nitrocellulose transfer membrane.
Membranes were blocked in 5% non-fat dry-milk and incubated overnight
at 4 1C with the primary antibodies. A mouse anti-b-actin antibody from
Sigma-Aldrich (St Louis, MO, USA) was used as a loading control. Signals
were detected with the ECL Plus reagent and a ImageQuant LAS4000
detection system (GE Healthcare Europe GmbH, Freiburg, Germany).25
Cell cycle analysis
Cell cycle analysis was performed using propidium iodide (PI)/RNase A
staining according to standard techniques, as described elsewhere.26
Samples were analyzed on a EPICS XL ﬂow cytometer Beckman Coulter
(Miami, FL, USA) with the appropriate software (System II, Beckman
Coulter). At least 15 000 events/sample were acquired.
PI/Annexin V assay
Brieﬂy, apoptosis analysis was performed by staining with Annexin V/7-
AAD, using a Muse Cell Analyzer (Merck-Millipore). For primary cell analysis,
samples were incubated with Annexin V-ﬂuorescein isothiocyanate (FITC)
and PI.27 Samples were analyzed on a FC500 ﬂow cytometer by Beckman
Coulter.
siRNA downregulation of beclin-1
This was accomplished using 100 nM of either control (scrambled) or
Beclin-1-speciﬁc siRNA, essentially as described elsewhere.28
Combined drug effect analysis
To characterize the effect of either RAD001/MK-2206 or CCI-779/GSK
690693 administered in combination and their potential synergy, data
were evaluated from quantitative analysis of dose-effect relationship, as
described previously. For each combination experiment, a combination
index (CI) number was calculated using the Biosoft CalcuSyn software
(Biosoft, Cambridge, UK). This method of analysis generally deﬁnes CI
values from 0.9 to 1.1 as additive, from 0.3 to 0.9 as synergistic ando0.3 as
strongly synergistic, whereas values41.1 are considered as antagonistic.29
Statistical evaluation
The data are presented as mean values from three separate experi-
ments±s.d. Data were statistically analyzed by a Dunnet test after one-way
analysis of variance (ANOVA) at a level of signiﬁcance of Po0.05 vs control
samples.
RESULTS
The PI3K/Akt/mTOR pathway activation status and RAD001 effects
in B-pre ALL cell lines
By western blotting, the PI3K/Akt/mTOR pathway activation status
in B-pre ALL cell lines was ﬁrst evaluated. Ser 473 p-Akt and Ser
2481 p-mTOR (indicative of mTORC2 activity)30 were maximally
phosphorylated in SEM cells and, to a lower extent, in RS4;11 cells,
whereas REH cells displayed very low levels of Ser 473 p-Akt
phosphorylation. Also Ser 2448 p-mTOR levels (a readout for
mTORC1 activity)30 were higher in SEM cells than in either RS4;11
or REH cells (Figure 1a). Phosphatase and tensin homolog PTEN, a
negative regulator of the PI3K/Akt/mTOR pathway,31 was much
more abundantly expressed in REH cells.
We next examined the RAD001 cytotoxic effects on B-pre ALL
cell lines. Cell lines were treated with increasing concentrations of
RAD001 for 48 h and then analyzed by MTT assays. Cell viability
decreased in a dose-dependent manner. Under these conditions,
the RAD001 IC50 for cell lines ranged between 6.3 and 10.4 mM. It is
noteworthy that SEM cells were the most sensitive to RAD001
when compared with the other cell lines (Figure 1b). The cytotoxic
effects of RAD001 on SEM, REH and NALM6 cells were also studied
by ﬂow cytometry analysis of Annexin V-stained samples. Overall,
the results were similar to those obtained with MTT assays,
displaying a concentration-dependent increase of apoptotic cells
(Figure 1c).
RAD001 modulates PI3K/Akt/mTOR signaling in B-pre ALL cell lines
We studied the effects of RAD001 on the phosphorylation levels of
critical components of the PI3K/Akt/mTOR cascade. REH, SEM and
RS4;11 cells were treated with increasing concentrations of
RAD001 for 4 h and then analyzed by western blotting
(Figure 2a). RAD001 not only decreased the phosphorylation
levels of mTOR mainly on the Ser 2448 residue (a readout for
mTORC1 activity) but also on the Ser 2481 phosphorylation site (a
marker for mTORC2 activity). The total amount of mTOR was
unchanged. mTORC1 inhibition had functional effects on two well-
known mTORC1 substrates, p70S6K and 4EBP1. p70S6K was
completely dephosphorylated already at 2 mM concentration of
RAD001, whereas 4EBP1 was dephosphorylated starting at a
higher concentration. Total levels of these two proteins were
instead unaffected by RAD001.
RAD001 also decreased the levels of Ser 473 p-Akt, p-GSK3-a/b
on Ser 21/9 and p-Forkhead box O3A (FoxO3A) on Ser 318/321 in
SEM cells. Interestingly, FoxO3A transcription factor was fully
dephosphorylated already at 2 mM RAD001 only in SEM cell line
(Figure 2b).
RAD001 induces cell cycle arrest, apoptosis and autophagy
To assess the effects of RAD001 on cell cycle, we performed ﬂow
cytometric analysis of PI-stained samples in REH and SEM cells
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Figure 1. PI3K/Akt/mTOR signaling activation and RAD001 sensitivity of B-pre ALL cell lines. (a) Western blot analysis for phosphorylation
levels of critical components of the PI3K/Akt/mTOR signaling network. Protein (50 mg) was blotted to each lane. An antibody to b-actin
documented equal lane loading. (b) Cell viability of B-pre ALL cell lines treated with increasing concentrations of RAD001 for 48 h.
(c) Assessment of cell viability and apoptosis induction by RAD001 in SEM, REH and NALM6 cells. In b and c, one representative of three
different experiments that yielded similar results is shown. Viability was assessed by MTT assays, whereas apoptosis was assessed by Annexin
V/7-AAD staining.
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Figure 2. Effects of RAD001 on the phosphorylation levels of key components of the PI3K/Akt/mTOR pathway after 4 h of treatment with
increasing concentrations of the drug. (a) Western blot analysis for mTOR and its downstream targets, p70S6K and 4EBP1. (b) Western blot
analysis for Akt, GSK3-a/b and FoxO3A. In a and b, 50mg of protein was blotted to each lane. b-actin served as a loading control.
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cultured for 24 h in the presence of increasing concentrations of
RAD001. RAD001 increased dose dependently the percentage of
cells in the G0/G1 phase of the cell cycle with a concomitant
decrease of cells in S and G2/M phases (Figure 3a).
Apoptosis and autophagy, two central mechanisms for
programmed cell death,32 have important roles in the killing of
malignant cells. To elucidate whether RAD001 cytotoxic effects
were related to apoptosis and/or autophagy, we analyzed REH,
SEM and RS4;11 cell lysates by western blotting. The cells were
treated for 4 h with increasing concentrations of RAD001.
Procaspase-9 and poly-(ADP-ribose)polymerase (PARP) were
cleaved in a dose-dependent manner in all the three cell lines,
but the apoptotic effect of RAD001 was more evident in SEM cells
(Figure 3b).
Autophagy can be a form of programmed cell death, but is also
involved in protective mechanisms against apoptosis.33
Microtubule-associated protein 1 light chain 3 (LC3A/B) is a
structural component in the formation of autophagosomes and is
widely used as an autophagic marker, as its lipidated form (LC3A/
B-II) monitors the occurrence of autophagy.34 To evaluate whether
or not the treatment with RAD001 could lead to autophagy, we
detected the expression of LC3A/B-I (non lipidated) and LC3A/B-II
(lipidated) by western blotting. The expression levels of LC3A/B-II
gradually increased in the three cell lines in a dose-dependent
manner, but were more evident in SEM cells (Figure 3c).
Another protein critically involved in autophagy is Beclin-1,
which is responsible for autophagosome formation, and its
deletion has been reported to increase the incidence of
spontaneous tumorigenesis, abnormal proliferation of mammary
epithelial cells and germinal center B lymphocytes.33
Therefore, we downregulated Beclin-1 expression by transfect-
ing SEM cells with Beclin-1 siRNA (Figure 4a) and measured cell
viability by MTT assay after cell exposure to increasing concentra-
tions of RAD001. Analysis of the data showed that cells with
silenced Beclin-1 were more resistant to RAD001 than the control
(untreated) cells and the cells treated with scrambled
siRNA (Figure 4c). Similar results were obtained with REH cells
(Figures 4b–d).
These results indicated that autophagy is a critical determinant
of the cytotoxic effects induced in B-pre ALL cells by RAD001.
Dual targeting of mTOR and Akt results in synergistic inhibition of
proliferation in B-pre ALL cell lines
For therapeutic targeting of the PI3K/Akt/mTOR pathway, the
combined inhibition at different points of the cascade often leads
to more effective results than the use of a drug that acts on a
single or dual targets. However, most of the studies in this ﬁeld
have been performed in solid tumor models.35–38
Therefore, we decided to evaluate whether the simultaneous
administration of RAD001 and MK-2206 could lead to synergistic
cytotoxic effects in B-pre ALL cell lines. MK-2206 is a novel, orally
active, allosteric pan-Akt inhibitor, whose effectiveness has been
proven in preclinical models of human cancers and is undergoing
phase I/II clinical trials.39,40 More than one strategy was used to
determine whether the two inhibitors could synergize. In the ﬁrst
condition, cells were treated with the two drugs simultaneously
for 48 h. In the second condition, the ﬁrst drug was administered
during the entire experiment (48 h), whereas the second drug was
added only for the last 24 h of the treatment. Then, MTT assays
were performed. As shown in Figure 5a, in SEM cells, all the
conditions were tested, and the strongest synergy was observed
when RAD001 was added ﬁrst and MK-2206 was added second.
In REH, RS4;11 and NALM6 cells, RAD001 was combined with
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a
b
c
100
CTRL
RAD001 0.5M 100
* * *
75
RAD001 2M
RAD001 5M
CTRL
RAD001 0.5M
RAD001 2M
RAD001 5M75
50 50
* *
* *
*
*25 25
* * *
0 0
G0/G1 S G2/M G0/G1 S G2/M
REH SEM RS4;11
RAD001 [M]  (4h) 8 15
Caspase-9
Cleaved Caspase-9
PARP
-actin
-Actin
LC3A/B I
LC3A/B II
* * *
***
0 2 8 150 2 8 150 2
REH SEM RS4;11
RAD001 [M]  (4h) 8 150 2 88 150 2 150 2
Figure 3. RAD001-induced cell cycle arrest, apoptosis and autophagy in B-pre ALL cell lines. (a) Cell cycle was analyzed by flow cytometry after
PI staining. The results are the mean±s.d. of three different experiments. Asterisks (*) indicate significant differences (Po0.05) in comparison
with control. (b) Western blot analysis for caspase-9 and PARP cleavage in B-pre ALL cell lines. (c) Western blot analysis demonstrating
increased expression of the fast-migrating (lipidated) form of LC3A/B in cell lines treated with RAD001. In b and c an antibody to b-actin
documented equal lane loading.
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MK-2206 for 48 h. A synergistic inhibition of cell viability was
observed for all cell lines (Figures 5b–d).
We next studied the effects of the RAD001/MK-2206
combination on the PI3K/Akt/mTOR pathway in SEM cells by
western blotting analysis of the phosphorylation levels of 4EBP1
and GSK3-a/b. The cells were treated with 0.34 mM RAD001
for 48 h and with 1 mM MK-2206 for the last 24 h. The two
proteins were much more efﬁciently dephosphorylated by the
drug combination than that by either drug employed alone
(Figure 6a).
Moreover, RAD001 and MK-2206, when administered together,
increased apoptosis through extrinsic and intrinsic pathways, as
documented by the increment of cleaved caspase-8, -9 and PARP
(Figure 6b). Furthermore, increased levels of lipidated LC3A/B
suggested that the drugs acted together for potentiating
autophagy induction (Figure 6b). The effects of the RAD001 and
MK-2206 combination were also analyzed in NALM6 cells. Also, in
this cell line, GSK3-a/b and 4EBP1 were much more efﬁciently
dephosphorylated by the drug combination than by either drug
employed alone. Moreover, upregulated lipidation of LC3A/B
indicated that the drugs synergized in potentiating autophagy
induction (Figure 6c).
The increase in the percentage of G0/G1 phase cells and the
concomitant decrease in both S and G2/M phases were more
evident when RAD001 and MK-2206 were used in combination in
SEM cells (Figure 6d).
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The tumor suppressor protein retinoblastoma (Rb) in the
phosphorylated state (p-Rb) is active and exert its role by
promoting cell cycle progression from G1 to S phase.
41 Western
blotting analysis documented that in SEM cells, dual treatment
with RAD001 and MK-2206 maximally reduced the levels of
phosphorylated Rb protein on Ser 807/811 and Ser 780 residues
(Figure 6e). This effect was consistent with the arrest of B-pre ALL
cells in G0/G1 phase of the cell cycle.
To conﬁrm these ﬁndings, we employed a different mTORC1/
Akt inhibitor combination, consisting of CCI-779 and GSK 690693.
SEM and NALM6 cells were treated with the two drugs
simultaneously for 48 h. Then, MTT assays were performed.
As shown in Figures 7a and b, the two drugs synergized to
inhibit cell viability. We next studied the effects of the drug
combination by western blotting analysis of the phosphorylation
levels of 4EBP1 and GSK3-a/b. The two proteins were much more
efﬁciently dephosphorylated by the drug combination than that
by either drug employed alone (Figures 7c and d). As different
inhibitors yielded similar results, it was concluded that there were
no off-target drug effects implicated in the described ﬁndings.
B-pre ALL lymphoblasts are sensitive to combined mTOR/Akt
inhibition
To establish the efﬁcacy of the inhibitors as potential therapeutic
agents for B-pre ALL, we analyzed four B-pre ALL adult patient
samples isolated from peripheral blood/bone marrow. Available
patient characteristics are presented in Supplementary Table T1.
Samples were treated with either RAD001 or MK-2206 alone or
with the combination of 0.34 mM RAD001 and 1 mM MK-2206 for
72 h. In the two patients shown in Figure 8a, RAD001 induced a
downregulation Ser 473 p-Akt, Ser 2448 p-mTOR and Thr 389
p-p70S6K levels. In the same two patients, we tested the
synergistic effects of RAD001 and MK-2206 on 4EBP1 and
GSK3-a/b. The decrease in the phosphorylation levels of the two
proteins was much higher when the two drugs were used in
combination than as single agents. Autophagic induction in the
primary samples was also more effective when the two drugs
were combined together as indicated by the levels of lipidated
LC3A/B (Figure 8b).
Dual targeting of mTOR and Akt also increased apoptosis in
patient primary cells. Cells were stained by PI/Annexin V-FITC and
analyzed by ﬂow cytometry. After 48 h of treatment, when the two
drugs were administered together, the apoptotic cells raised to
50%, whereas RAD001 and MK-2206 alone induced apoptosis in
a percentage of 14% or 25%, respectively (Figure 8c).
In Figure 8d are shown the results of MTT assays of four
representative patients analyzed for cell viability after in vitro
treatment with either drugs used as single agents or combined
together. In all the patients studied, the drug combination
induced a stronger decrease in cell viability. Overall, these ﬁndings
demonstrated that the combination consisting of RAD001 and
MK-2206 reduced the growth of B-pre ALL primary cells. Moreover,
also the combination of CCI-779 and GSK 690693 caused
a stronger decrease in cell viability than that by either drug
employed alone (Supplementary Figure S1).
DISCUSSION
Deregulation of the PI3K/Akt/mTOR pathway contributes to cancer
cell survival, promotes chemotherapy resistance through
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disruption of apoptosis and initiates cap-dependent translation of
mRNAs essential for cell cycle progression, differentiation and
growth.42 Activation of this pathway is a common feature of a
wide range of human cancers43 and is an indicator of poor
prognosis.44–48 Thus, it is reasonable to assume that targeting
mTOR using the orally active rapamycin derivative RAD001 can
effectively contribute to treat tumors with hyperactivation of PI3K/
Akt/mTOR signaling. In this study, we demonstrated the efﬁcacy of
RAD001 as a potential therapeutic inhibitor of the PI3K/Akt/mTOR
pathway in B-pre ALL cells.
RAD001 was cytotoxic to B-pre ALL cell lines in a concentration-
dependent manner, which was demonstrated by both MTT assays
and ﬂow cytometric analysis of Annexin V-stained samples.
Cytotoxicity was independent from the t4;11 translocation, which
occurs in SEM and RS4;11 cell lines.
In B-pre ALL cell lines, RAD001 not only downregulated
mTORC1 activity (as documented by dephosphorylation of Ser
2448 p-mTOR, Thr 389 p-p70S6K and Thr 37/46 p-4EBP1) but also
decreased mTORC2 activity, as demonstrated by decreased
phosphorylation of Ser 473 p-Akt and Ser 2481 p-mTOR.
The downmodulation of mTORC2 by RAD001 had been
reported in AML.49 However, in AML RAD001 was effective in
inhibiting mTORC2 formation only when used for long incubation
times (at least 24 h), whereas in B-pre ALL cell lines, a 4 h
incubation was sufﬁcient to block mTORC2 activity. This could
indicate that B-pre ALL cell lines are very sensitive to RAD001.50
The cytotoxic effects of RAD001 on B-pre ALL cell lines could be
related to cell cycle arrest in G0/G1, and induction of either
apoptosis or autophagy (or both). Remarkably, both apoptosis and
autophagy were more evident in SEM cells, consistently with the
highest sensitivity of this cell line to RAD001.
Cancer cells can gain beneﬁt of autophagy as a survival
mechanism, which gives them a selective advantage to tolerate
metabolic stress and to contrast apoptosis.51 We found that
silencing Beclin-1, a protein essential for the assembly of the
autophagy initiation complex that leads to autolysosomes
formation,33 resulted in a lower sensitivity of both SEM and REH
cells to the cytotoxic effects of RAD001. Therefore, RAD001-
induced autophagy is very important for the reduction of cell
viability. Although the induction of autophagy by RAD001 in B-pre
ALL cells has been previously reported,52 this is the ﬁrst time that
the functional signiﬁcance of autophagy was explored. We aimed
in investigating the effect of combined Akt and mTOR inhibition
on B-pre ALL cells using the novel allosteric, clinically available
pan-Akt inhibitor MK-2206.29 This combination has been
demonstrated to be effective in hepatocellular carcinoma cell
lines,53 cholangiocarcinoma cell lines38 and in an in vivo model of
castration-resistant prostate cancer.54 Moreover, we used a second
combination consisting of CCI-779 and GSK 690693.
There is a strong rationale for targeting Akt in B-pre ALL cells, as
a recent work has documented that Akt activation is associated in
this leukemia subset with poor prognosis and resistance to a set of
chemotherapeutic drugs, including prednisolone, dexamethasone,
vincristine and adriamycin.48
We observed a synergistic cytotoxic effect of the RAD001/MK-
2206 drug combination. The combination caused a dose-
dependent decrease of cell viability, and this was visible even at
low concentrations in all cell lines, but especially in SEM cells. After
testing different strategies for combining the two drugs together,
we observed that the highest synergistic effects were detectable
in SEM cells when RAD001 was administered for 48 h and MK-2206
was added after 24 h. We are at present investigating the
mechanisms underlying this peculiar behavior.
The combination consisting of RAD001 and MK-2206 was more
effective than either treatment alone in inducing cell cycle arrest
in G0/G1, and this correlated with a more effective dephoshoryla-
tion of Rb on both Ser 807/811 and Ser 780. These two
residues are key determinants of Rb activity. Indeed, it has been
documented that a Rb mutant with alanine substitutions at Ser
807/811 had enhanced growth-suppressing activity.55 Moreover,
phosphorylation of Ser 807/811 led to an inactivation of Rb tumor
suppressor activity in uveal melanoma.56 The Ser 807/811 and Ser
780 residues are targets of cyclin E/CDK2 and cyclin D/CDK4,
respectively.57 It should be reminded here that mTORC1 controls
the translation of several proteins that are of critical importance
for cell cycle progression, including CDK2.50 It is important to
emphasize that Rb gene activation is an unfavorable prognostic
predictor in initial and relapsed childhood ALL.58 Therefore, drugs
that affect the Rb pathway activity may be important for
development of individual-targeted therapies.
The dual mTOR/Akt inhibition was more effective than single
drugs in lowering cell viability and affecting phosphorylation of
critical components of the PI3K/Akt/mTOR pathway, also if we
employed a different drug combination consisting of CCI-779 and
GSK 690693.
These ﬁndings may have a clinical relevance for B-pre ALL
patients, because the synergistic combination of the drugs led to
an increase of the cytotoxic activity at lower concentrations of the
inhibitors. If this would be translated into the clinic, an attenuation
of toxic side effects could be expected.
RAD001 alone displayed anti-leukemic effects also against B-pre
ALL patient samples, acting on Ser 473 p-Akt, Ser 2448 p-mTOR
and Thr 389 p-p70S6K.
Consistently, also in B-pre ALL lymphoblasts, we observed a
striking synergistic effect of the combination of RAD001/MK-2206
that resulted in increased dephosphorylation of key components
of the PI3K/Akt/mTOR pathway, as well as in enhanced apoptosis
and decreased cell viability. Also the CCI-779 and GSK 690693
combination affected B-pre ALL lymphoblasts viability more
effectively than either drug alone.
In conclusion, we have documented that RAD001 is cytotoxic to
B-pre ALL cells, and that autophagy has an important role in
decreasing cell viability. Moreover, our ﬁndings suggest that
rapamycin derivatives can be effectively used in combination with
other inhibitors targeting key nodes of the PI3K/Akt/mTOR
pathway, in order to reduce drug concentration and hence
systemic side effects. Therefore, dual targeting of PI3K/Akt/mTOR
signaling pathway might represent a new promising therapeutic
strategy for treatment of adult B-pre ALL patients.
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